Annual EBITDA
-$251.43 M
-$116.15 M-85.86%
December 31, 2023
Summary
- As of February 7, 2025, NMRA annual EBITDA is -$251.43 million, with the most recent change of -$116.15 million (-85.86%) on December 31, 2023.
- During the last 3 years, NMRA annual EBITDA has fallen by -$156.02 million (-163.52%).
- NMRA annual EBITDA is now -163.52% below its all-time high of -$95.41 million, reached on December 1, 2020.
Performance
NMRA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$76.49 M
-$12.83 M-20.15%
September 30, 2024
Summary
- As of February 7, 2025, NMRA quarterly EBITDA is -$76.49 million, with the most recent change of -$12.83 million (-20.15%) on September 30, 2024.
- Over the past year, NMRA quarterly EBITDA has dropped by -$16.57 million (-27.66%).
- NMRA quarterly EBITDA is now -399.51% below its all-time high of -$15.31 million, reached on March 1, 2021.
Performance
NMRA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$313.91 M
-$19.80 M-6.73%
September 30, 2024
Summary
- As of February 7, 2025, NMRA TTM EBITDA is -$313.91 million, with the most recent change of -$19.80 million (-6.73%) on September 30, 2024.
- Over the past year, NMRA TTM EBITDA has dropped by -$41.57 million (-15.26%).
- NMRA TTM EBITDA is now -1512.67% below its all-time high of -$19.46 million, reached on December 1, 2020.
Performance
NMRA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NMRA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -85.9% | -27.7% | -15.3% |
| 3 y3 years | -163.5% | -145.5% | -12.7% |
| 5 y5 years | - | -145.5% | -12.7% |
NMRA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -85.9% | at low | -189.6% | +32.8% | -139.4% | at low |
| 5 y | 5-year | -163.5% | at low | -399.5% | +57.0% | -1512.7% | at low |
| alltime | all time | -163.5% | at low | -399.5% | +57.0% | -1512.7% | at low |
Neumora Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$76.49 M(+20.2%) | -$313.91 M(+6.7%) |
| Jun 2024 | - | -$63.66 M(+6.3%) | -$294.11 M(+8.0%) |
| Mar 2024 | - | -$59.92 M(-47.4%) | -$272.34 M(+8.3%) |
| Dec 2023 | -$251.43 M(+85.9%) | -$113.84 M(+100.8%) | -$251.43 M(+49.5%) |
| Sep 2023 | - | -$56.69 M(+35.3%) | -$168.16 M(+18.5%) |
| Jun 2023 | - | -$41.89 M(+7.4%) | -$141.93 M(+8.2%) |
| Mar 2023 | - | -$39.01 M(+27.6%) | -$131.20 M(-3.0%) |
| Dec 2022 | -$135.28 M | -$30.57 M(+0.4%) | -$135.28 M(+3.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$30.46 M(-2.3%) | -$131.12 M(-52.9%) |
| Jun 2022 | - | -$31.16 M(-27.7%) | -$278.65 M(+5.3%) |
| Mar 2022 | - | -$43.09 M(+63.1%) | -$264.56 M(+11.7%) |
| Dec 2021 | -$236.78 M(+148.2%) | - | - |
| Dec 2021 | - | -$26.42 M(-85.2%) | -$236.78 M(+3.0%) |
| Sep 2021 | - | -$177.98 M(+942.3%) | -$229.83 M(+343.2%) |
| Jun 2021 | - | -$17.07 M(+11.5%) | -$51.85 M(+49.1%) |
| Mar 2021 | - | -$15.31 M(-21.3%) | -$34.78 M(+78.7%) |
| Dec 2020 | -$95.41 M | -$19.46 M | -$19.46 M |
FAQ
- What is Neumora Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Neumora Therapeutics?
- What is Neumora Therapeutics annual EBITDA year-on-year change?
- What is Neumora Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Neumora Therapeutics?
- What is Neumora Therapeutics quarterly EBITDA year-on-year change?
- What is Neumora Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Neumora Therapeutics?
- What is Neumora Therapeutics TTM EBITDA year-on-year change?
What is Neumora Therapeutics annual EBITDA?
The current annual EBITDA of NMRA is -$251.43 M
What is the all time high annual EBITDA for Neumora Therapeutics?
Neumora Therapeutics all-time high annual EBITDA is -$95.41 M
What is Neumora Therapeutics annual EBITDA year-on-year change?
Over the past year, NMRA annual EBITDA has changed by -$116.15 M (-85.86%)
What is Neumora Therapeutics quarterly EBITDA?
The current quarterly EBITDA of NMRA is -$76.49 M
What is the all time high quarterly EBITDA for Neumora Therapeutics?
Neumora Therapeutics all-time high quarterly EBITDA is -$15.31 M
What is Neumora Therapeutics quarterly EBITDA year-on-year change?
Over the past year, NMRA quarterly EBITDA has changed by -$16.57 M (-27.66%)
What is Neumora Therapeutics TTM EBITDA?
The current TTM EBITDA of NMRA is -$313.91 M
What is the all time high TTM EBITDA for Neumora Therapeutics?
Neumora Therapeutics all-time high TTM EBITDA is -$19.46 M
What is Neumora Therapeutics TTM EBITDA year-on-year change?
Over the past year, NMRA TTM EBITDA has changed by -$41.57 M (-15.26%)